| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
19,740,000 |
| Market
Cap: |
4.17(B) |
| Last
Volume: |
9,322,967 |
Avg
Vol: |
9,297,189 |
| 52
Week Range: |
$120.4 - $292.92 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Diagnostic Substances |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 27 |
| Insider 3/6 Months : 27.6 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Co.'s primary product candidate, resmetirom, is being developed as a once-daily oral pill to treat several disease states, including non-alcoholic steatohepatitis, or NASH. Co. has initiated MAESTRO-NASH, a Phase 3 trial in NASH with its once daily, oral thyroid hormone receptor beta selective agonist, resmetirom. Co. has opened for enrollment MAESTRO-NAFLD-1, a Phase 3 clinical study of patients with biopsy-confirmed or presumed NASH recruited from sites in the U.S.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
424,685 |
424,685 |
424,685 |
| Total Buy Value |
$0 |
$77,751,391 |
$77,751,391 |
$77,751,391 |
| Total People Bought |
0 |
1 |
1 |
1 |
| Total Buy Transactions |
0 |
10 |
10 |
10 |
| Total Shares Sold |
252,542 |
270,142 |
270,142 |
339,631 |
| Total Sell Value |
$62,399,106 |
$66,219,580 |
$66,219,580 |
$85,688,008 |
| Total People Sold |
5 |
7 |
7 |
8 |
| Total Sell Transactions |
13 |
21 |
21 |
26 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Friedman Paul A |
Chief Executive Officer |
• • – |
2023-01-16 |
4 |
A |
$0.00 |
$0 |
D/D |
26,668 |
26,668 |
|
- |
|
| Taub Rebecca |
Pres., R&D, and CMO |
• • – |
2023-01-16 |
4 |
A |
$0.00 |
$0 |
D/D |
20,001 |
20,001 |
|
- |
|
| Lynch Brian Joseph |
SVP and General Counsel |
• – – |
2023-01-16 |
4 |
A |
$0.00 |
$0 |
D/D |
15,001 |
15,001 |
|
- |
|
| Sukhija Remy |
Chief Commercial Officer |
• – – |
2023-01-16 |
4 |
A |
$0.00 |
$0 |
D/D |
15,001 |
15,001 |
|
- |
|
| Waltermire Robert E. |
Senior VP, Chief Pharma Dev. |
• – – |
2023-01-16 |
4 |
A |
$0.00 |
$0 |
D/D |
5,667 |
5,667 |
|
- |
|
| Lynch Brian Joseph |
SVP and General Counsel |
• – – |
2022-12-23 |
4 |
AS |
$267.88 |
$1,919,231 |
D/D |
(7,000) |
0 |
|
12% |
|
| Lynch Brian Joseph |
SVP and General Counsel |
• – – |
2022-12-23 |
4 |
OE |
$91.79 |
$642,530 |
D/D |
7,000 |
7,000 |
|
- |
|
| Sukhija Remy |
Chief Commercial Officer |
• – – |
2022-12-23 |
4 |
AS |
$266.04 |
$8,224,073 |
D/D |
(30,000) |
0 |
|
12% |
|
| Sukhija Remy |
Chief Commercial Officer |
• – – |
2022-12-23 |
4 |
OE |
$60.26 |
$1,807,800 |
D/D |
30,000 |
30,000 |
|
- |
|
| Craves Fred B |
Director |
– • • |
2021-12-03 |
4 |
D |
$0.00 |
$0 |
I/I |
(824,172) |
1,261 |
|
- |
|
| Bay City Capital Fund Iv Co Invesment Fund Lp |
10% Owner |
– – • |
2021-12-03 |
4 |
D |
$0.00 |
$0 |
D/D |
(24,172) |
1,261 |
|
- |
|
| Bay City Capital Fund Iv Co Invesment Fund Lp |
10% Owner |
– – • |
2021-12-03 |
4 |
D |
$0.00 |
$0 |
I/I |
(800,000) |
0 |
|
- |
|
| Bay City Capital Fund Iv Co Invesment Fund Lp |
10% Owner |
– – • |
2020-12-01 |
4 |
D |
$0.00 |
$0 |
I/I |
(43,537) |
2,310,521 |
|
- |
|
| Craves Fred B |
Director |
– • • |
2020-09-04 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,545,460) |
43,537 |
|
- |
|
| Bay City Capital Fund Iv Co Invesment Fund Lp |
10% Owner |
– – • |
2020-09-04 |
4 |
D |
$0.00 |
$0 |
D/D |
(45,460) |
43,537 |
|
- |
|
| Bay City Capital Fund Iv Co Invesment Fund Lp |
10% Owner |
– – • |
2020-09-04 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,500,000) |
49,730 |
|
- |
|
| Craves Fred B |
Director |
– • • |
2020-08-19 |
4 |
S |
$107.64 |
$786,095 |
I/I |
(7,303) |
42,875 |
|
-4% |
|
| Bay City Capital Fund Iv Co Invesment Fund Lp |
10% Owner |
– – • |
2020-08-19 |
4 |
S |
$107.64 |
$786,095 |
D/D |
(7,303) |
42,875 |
|
-4% |
|
| Craves Fred B |
Director |
– • • |
2020-08-18 |
4 |
S |
$110.03 |
$1,121,976 |
I/I |
(10,197) |
50,178 |
|
-2% |
|
| Bay City Capital Fund Iv Co Invesment Fund Lp |
10% Owner |
– – • |
2020-08-18 |
4 |
S |
$110.03 |
$1,121,976 |
D/D |
(10,197) |
50,178 |
|
-2% |
|
| Craves Fred B |
Director |
– • • |
2020-08-17 |
4 |
S |
$110.73 |
$1,384,125 |
I/I |
(12,500) |
60,375 |
|
1% |
|
| Bay City Capital Fund Iv Co Invesment Fund Lp |
10% Owner |
– – • |
2020-08-17 |
4 |
S |
$110.73 |
$1,384,125 |
D/D |
(12,500) |
60,375 |
|
1% |
|
| Bay City Capital Fund Iv Co Invesment Fund Lp |
10% Owner |
– – • |
2020-05-27 |
4 |
D |
$0.00 |
$0 |
D/D |
(44,903) |
72,875 |
|
- |
|
| Bay City Capital Fund Iv Co Invesment Fund Lp |
10% Owner |
– – • |
2020-05-27 |
4 |
D |
$0.00 |
$0 |
I/I |
(367,333) |
81,380 |
|
- |
|
| Craves Fred B |
Director |
– • • |
2020-05-27 |
4 |
D |
$0.00 |
$0 |
I/I |
(412,236) |
72,875 |
|
- |
|
413 Records found
|
|
Page 4 of 17 |
|
|
6.07 (2.96%) 
